🔗 Share this article

While America undertakes historic revisions to its vaccination guidelines, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by casting doubt on Covid vaccines throughout the global health crisis and has zeroed in on possible deaths following COVID-19 immunization in her recent tenure at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Public health authorities were set to reveal sweeping changes to the pediatric immunization program in December, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of step with much of the international standard with little proof for improved outcomes. The planned update has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the event. She was recently named temporary leader of the FDA’s CDER, the fifth person to run the office this calendar year.

A Shift at the Agency

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon dismantling long-standing immunizations at the FDA.

The new acting director has repeatedly called for halting specific childhood immunization guidelines in the US to become more like the Danish model, a nation with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – usually the domain of Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Qualifications

Dr. Høeg has no apparent track record in medication creation, oversight or administrative roles, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the CDER, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a major agency. She has no expertise in industry regulation.”

Past commissioners of CBER would “understand laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who led CBER have had.”

This division has an vast portfolio at the agency, the former commissioner stated.

“Everybody just pays attention on the new drug program, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and every single one have to be looked after,” she noted. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a significant management aspect to the role, which oversees over 5,000 employees. “It is a huge administrative position, if you do it right,” Woodcock added.

Official Statement and Controversial Initiatives

In response to concerns about Høeg’s fitness for the role and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson stated that the “questions stem from incorrect presumptions”.

“This background matches the responsibilities of her position,” the spokesperson said, noting the time Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg takes over the agency head's recently launched expedited review system, a contentious one-day drug-approval program that apparently troubled her former heads. “How are these medications being picked for this voucher program? Who is making the calls?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the agency appears to be shifting towards more relaxed rules of all drugs, aside from shots.”

Established Past Work on Vaccines

With immunizations, Dr. Høeg has a more documented, if troubling, past, Howard have noted. She published a research paper using unconfirmed crowd-sourced reports to assess the incidence of heart inflammation after COVID-19 vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the new administration encompassed revising regulations for novel immunizations and halting “optional” immunizations, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has reportedly proposed preventing adolescent males from getting COVID-19 vaccinations.

“She is an all-around dogmatist who commences with her beliefs and tailors the evidence to fit the data in a extremely deceptive, untruthful way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|